Revvity, Inc. (RVTY) KPIs and segments
Close on Nov 18, 2026Market cap $17.01BP/E 72.6Yield 0.18%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Revvity · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Revvity: 33 chỉ số vận hành, trong đó có Unbilled Software & Contract Receivables, Total Deferred Revenue và Customer Deposits (Recognized Within 3 Months), lấy từ 210 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diagnostics($M)3 | 371 | 349 | 390 | 356 | 354 | 324 | 355 | 345 | 343 | 313 | 210 | ||
Americas($M) | 142 | 130 | 129 | 129 | 127 | 120 | 125 | 117 | 118 | 118 | 49.9 | ||
Europe($M) | 140 | 131 | 137 | 119 | 119 | 106 | 109 | 107 | 110 | 101 | 75.4 | ||
Asia($M) | 89.4 | 87.5 | 124 | 108 | 109 | 98.2 | 120 | 121 | 115 | 94.5 | 85.0 | ||
Life Sciences($M)3 | 359 | 362 | 382 | 343 | 366 | 340 | 375 | 339 | 349 | 337 | 486 | ||
Americas($M) | 184 | 186 | 191 | 178 | 197 | 184 | 193 | 185 | 190 | 177 | 251 | ||
Europe($M) | 89.5 | 91.7 | 99.9 | 83.3 | 84.3 | 76.0 | 88.1 | 75.1 | 74.6 | 77.5 | 117 | ||
Asia($M) | 85.6 | 84.6 | 90.7 | 81.4 | 84.5 | 80.1 | 93.3 | 78.2 | 84.2 | 82.5 | 117 | ||
Product($M) | 603 | 581 | 647 | 573 | 611 | 563 | 620 | 580 | 589 | 549 | 612 | ||
Service($M) | 126 | 130 | 125 | 126 | 110 | 102 | 109 | 104 | 103 | 101 | 83.4 | ||
Americas($M) | 326 | 316 | 320 | 307 | 324 | 305 | 319 | 302 | 308 | 294 | 301 | ||
Europe($M) | 229 | 223 | 237 | 202 | 204 | 182 | 197 | 182 | 185 | 179 | 192 | ||
Asia($M) | 175 | 172 | 214 | 189 | 193 | 178 | 213 | 200 | 199 | 177 | 202 | ||
Diagnostics($M) | 113 | 76.1 | 91.4 | 89.4 | 89.4 | 74.0 | 91.1 | 93.8 | 92.7 | 76.2 | |||
Life Sciences($M) | 112 | 104 | 136 | 101 | 115 | 106 | 138 | 111 | 118 | 101 | |||
Product($M) | 339 | 308 | 344 | 292 | 325 | 313 | 349 | 323 | 326 | 298 | 332 | ||
Service($M) | 77.8 | 79.5 | 77.9 | 82.1 | 67.4 | 63.0 | 63.6 | 61.4 | 59.4 | 56.9 | 51.1 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)3 | |||||||||||||
Unbilled Software & Contract Receivables($M)2 | 112 | 100 | 107 | 106 | 95.5 | 91.1 | 80.4 | 80.6 | 75.8 | ||||
Current Unbilled Receivables (in Accounts Receivable)($M) | 81.9 | 68.2 | 74.4 | 72.4 | |||||||||
Long-Term Unbilled Receivables (in Other Assets)($M) | 29.6 | 32.2 | 32.3 | 33.2 | |||||||||
Total Deferred Revenue (SaaS, Maintenance & Prepaid Storage)($M)2 | 236 | 240 | 239 | 225 | 224 | 225 | 223 | 213 | 210 | ||||
Current Deferred Revenue (Recognized Within 12 Months)($M) | 170 | 174 | 172 | 159 | |||||||||
Long-Term Deferred Revenue (Beyond 12 Months)($M) | 65.1 | 65.5 | 66.8 | 65.5 | |||||||||
Customer Deposits (Recognized Within 3 Months)($M) | 14.8 | 16 | 20.3 | 19.3 | 19.5 | 19 | 19.6 | 19.5 | 22.1 | ||||
Signals Software Franchise Revenue($M) | 67.5 | 57.7 | 61.8 | 62.3 | 52.3 | 67.8 | 53.9 | 61.8 | 43.3 | 50.7 | 44.9 | 45.6 | |
Immunodiagnostics Franchise Revenue($M)4 | 202 | 215 | 202 | 241 | 213 | 219 | 198 | 215 | 212 | 213 | 189 | 196 | |
Diagnostics Pro Forma Organic Sales Growth (Ex-China IDX)(%) | 5.0% | 11.0% | 9.0% | ||||||||||
Diagnostics Legacy As-Reported Organic Sales Growth(%) | 4.0% | 7.0% | 2.0% | 2.0% | 5.0% | 6.0% | 5.0% | 3.0% | 1.0% | -6.0% | |||
Diagnostics Foreign Exchange Revenue Impact(%) | -1.0% | 1.0% | 4.0% | 3.0% | 2.0% | 1.0% | -2.0% | -1.0% | 0.0% | -1.0% | -1.0% | 1.0% | |
Diagnostics Acquisitions & Divestitures Revenue Impact(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
Reproductive Health Franchise Revenue($M) | 147 | 156 | 147 | 149 | 143 | 136 | 127 | 140 | 134 | 130 | 125 | 127 | |
Legacy Applied Genomics Revenue (Reclassified to Life Sciences in FY2025)($M) | 53.3 | 52.7 | 51.3 | 47.4 | 52.5 | ||||||||
Finished Goods Inventory, Net($M)2 | 151 | 140 | 146 | 138 | 138 | 138 | 132 | 128 | 140 | 132 | 150 | 162 | |
Raw Materials Inventory, Net($M) | 169 | 167 | 170 | 173 | 175 | 181 | 182 | 175 | 194 | 198 | 194 | 197 | |
Work-in-Process Inventory, Net($M) | 68.9 | 71.8 | 71.5 | 69 | 67.1 | 69.1 | 68 | 65.2 | 71 | 71.4 | 69.4 | 69.2 | |
Life Sciences Solutions Franchise Revenue($M)6 | 312 | 301 | 300 | 320 | 291 | 298 | 287 | 313 | 296 | 298 | 292 | ||
Life Sciences Pro Forma Organic Sales Growth(%) | 9.0% | -3.0% | 3.0% | ||||||||||
Life Sciences Legacy As-Reported Organic Sales Growth(%) | 3.0% | 0.0% | 0.0% | 4.0% | 2.0% | 5.0% | -3.0% | -6.0% | -8.0% | -9.0% | |||
Life Sciences Foreign Exchange Revenue Impact(%) | 0.0% | 0.0% | 2.0% | 2.0% | 1.0% | 1.0% | -1.0% | 0.0% | 0.0% | -1.0% | 0.0% | 1.0% | |
Life Sciences Acquisitions & Divestitures Revenue Impact(%) | 2.0% | 1.0% | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
Legacy Life Sciences Reagents Revenue (Pre-FY2025 Consolidation)($M) | 186 | 179 | 177 | 177 | 179 | ||||||||
Legacy Life Sciences Instruments Revenue (Pre-FY2025 Consolidation)($M) | 88.1 | 78.8 | 86.3 | 80.9 | 95.3 | ||||||||
Adjusted Operating Income (Continuing Operations)($M)9 | 209 | 211 | 168 | 229 | 182 | 192 | 170 | 221 | 194 | 199 | 166 | 192 | |
Adjusted Operating Margin (Continuing Operations)(%) | 28.7% | 28.9% | 23.6% | 29.7% | 26.1% | 26.6% | 25.6% | 30.3% | 28.3% | 28.8% | 25.5% | 27.5% | |
GAAP Operating Margin (Continuing Operations)(%) | 13.1% | 12.2% | 10.7% | 14.5% | 11.7% | 12.6% | 10.9% | 16.3% | 14.3% | 12.4% | 6.8% | 11.1% | |
Pro Forma Revenue (Ex-China Immunodiagnostics Divestiture)($M) | 710 | 711 | 687 | 661 | 681 | 629 | |||||||
Pro Forma Adjusted Operating Income (Ex-China IDX)($M) | 209 | 209 | 165 | 172 | 180 | 159 | |||||||
Pro Forma Adjusted Operating Margin (Ex-China IDX)(%) | 29.4% | 29.3% | 24.0% | 26.0% | 26.5% | 25.3% | |||||||
Pro Forma Organic Sales Growth (Continuing Operations)(%) | 7.0% | 3.0% | 6.0% | ||||||||||
Legacy As-Reported Organic Sales Growth (Continuing Operations)(%) | 3.0% | 4.0% | 1.0% | 3.0% | 4.0% | 6.0% | 2.0% | -1.0% | -3.0% | -8.0% | |||
Foreign Exchange Impact on Consolidated Sales Growth(%) | -1.0% | 0.0% | 3.0% | 2.0% | 1.0% | 1.0% | -1.0% | -1.0% | 0.0% | -1.0% | 0.0% | 1.0% | |
Acquisitions & Divestitures Impact on Consolidated Sales Growth(%) | 1.0% | 1.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
Adjusted Diluted EPS (Continuing Operations)($)7 | 1.38 | 1.41 | 1.06 | 1.70 | 1.18 | 1.18 | 1.01 | 1.42 | 1.28 | 1.22 | 0.98 | 1.25 | |
Pro Forma Adjusted Diluted EPS (Ex-China IDX)($) | 1.37 | 1.41 | 1.04 | 1.13 | 1.15 | 0.95 | |||||||
Full-Year Organic Sales Growth Guidance — Low Bound(%) | 5.0% | 4.0% | 3.0% | ||||||||||
Full-Year Organic Sales Growth Guidance — High Bound(%) | 5.0% | 5.0% | 4.0% | ||||||||||
Full-Year Revenue Guidance — Low Bound($M) | 2,860 | 2,830 | 2,810 | ||||||||||
Full-Year Revenue Guidance — High Bound($M) | 2,860 | 2,860 | 2,840 | ||||||||||
Full-Year Adjusted Diluted EPS Guidance — Low Bound($) | 5.40 | 5.30 | 5.20 | ||||||||||
Full-Year Adjusted Diluted EPS Guidance — High Bound($) | 5.45 | 5.40 | 5.30 | ||||||||||
Free Cash Flow Conversion (% of Adjusted Net Income)(%)4 | 99.0% | 117.0% | 97.0% | 84.0% | |||||||||
Free Cash Flow (Management-Reported)($M) | 152 | 184 | 115 | 162 | |||||||||
Net Debt to Adjusted EBITDA Leverage Ratio(×) | 2.30 | 2.50 | 2.80 | ||||||||||
Adjusted Net Interest & Other Expense($M) | 21 | 22 | 23 | 23 | |||||||||
Adjusted Effective Tax Rate(%) | 18.0% | 16.0% | 18.3% | 6.5% | |||||||||
Life Sciences — Segment Cost of Revenue($M)4 | 136 | 127 | 132 | 132 | 130 | 135 | 119 | 127 | 118 | 120 | 124 | ||
Life Sciences — Segment SG&A Expenses($M) | 96.3 | 93.8 | 94.7 | 86.2 | 84.2 | 87 | 87.1 | 83.7 | 84.9 | 84.2 | 85.9 | ||
Life Sciences — Segment R&D Expenses($M) | 27.9 | 26.4 | 31.6 | 27.7 | 27.6 | 28.4 | 28.3 | 26.2 | 25.7 | 26.4 | 26.1 | ||
Life Sciences — Segment Depreciation Expense($M) | 9.30 | 8.20 | 9.90 | 9.30 | 8.50 | 8.50 | 7.20 | 5.10 | 8.70 | 8.10 | 8.30 | ||
Life Sciences — Segment Adjusted Operating Margin(%) | 31.5% | 31.1% | 28.7% | 29.5% | 31.6% | 31.1% | |||||||
Diagnostics — Segment Cost of Revenue($M)4 | 140 | 151 | 157 | 184 | 159 | 156 | 135 | 154 | 145 | 146 | 131 | ||
Diagnostics — Segment SG&A Expenses($M) | 85.1 | 84.7 | 90.2 | 84.7 | 84.7 | 84.1 | 89.9 | 86.3 | 84.1 | 83.1 | 82.6 | ||
Diagnostics — Segment R&D Expenses($M) | 20.1 | 22.6 | 26.2 | 30.4 | 23.1 | 24.8 | 25.3 | 22.8 | 22.6 | 21 | 23.5 | ||
Diagnostics — Segment Depreciation Expense($M) | 8.50 | 8.50 | 9.60 | 9.50 | 8.80 | 8.30 | 6.80 | 11.5 | 8.80 | 8 | 7.70 | ||
Diagnostics — Segment Adjusted Operating Margin(%) | 29.9% | 30.4% | 21.8% | 25.1% | 25.2% | 22.8% | |||||||
Unallocated Corporate Operating Expenses($M)1 | 14.5 | 13.4 | 12.2 | -2 | 8 | 13.1 | 9.80 | 8 | 10.9 | 11.4 | 11.4 | ||
Corporate Headquarters Depreciation Expense($M) | 0.40 | 0.40 | 0.50 | 0.80 | 0.70 | 0.70 | 0.70 | 0.60 | 0.50 | 0.60 | 0.60 | ||
Remaining Share Repurchase Program Authorization($M)2 | 793 | 793 | 801 | 880 | 210 | 415 | 857 | 355 | |||||
Common Shares Repurchased in Quarter (All Programs) | 806 | 94,873 | 835,257 | 1,763,295 | 2,324,351 | 3,103,930 | 1,561,183 | 45,905 | |||||
Average Price Paid Per Repurchased Share($) | 118 | 84.01 | 101 | 95.42 | 88.20 | 94.34 | 116 | 108 | |||||
Finite-Lived Intangible Assets, Net($M)5 | 2,138 | 2,224 | 2,307 | 2,347 | 2,426 | 2,514 | 2,571 | 2,641 | 2,763 | 2,826 | 2,919 | 3,022 | |
Intangible Asset Amortization Expense($M) | 84.7 | 84.9 | 85.1 | 83.5 | 84.1 | 85.3 | 82.7 | 87.9 | 89.6 | 90.6 | 91.2 | 89.6 | |
Scheduled Intangible Amortization — Next 12 Months / Year 1($M) | 313 | 313 | 313 | 332 | 332 | 333 | 328 | 332 | 337 | 333 | 333 | 363 | |
Scheduled Intangible Amortization — Year 2($M) | 287 | 287 | 287 | 305 | 305 | 305 | 301 | 326 | 331 | 327 | 327 | 335 | |
Scheduled Intangible Amortization — Year 3($M) | 257 | 257 | 257 | 279 | 279 | 279 | 275 | 299 | 304 | 300 | 300 | 329 | |
Scheduled Intangible Amortization — Year 4($M) | 228 | 228 | 228 | 249 | 249 | 250 | 246 | 273 | 278 | 274 | 275 | 302 | |
Property, Plant & Equipment Gross — Machinery & Equipment1 | |||||||||||||
Total Depreciation Expense($M) | 18.2 | 17.2 | 20 | 19.6 | 18 | 17.5 | 14.7 | 17.2 | 18 | 16.7 | 16.6 | ||
Restructuring Reserve Liability($M)1 | 45 | 32.8 | 14 | 17.8 | 3.80 | ||||||||
Environmental Loss Contingency Accrual($M) | 10.6 | 10.6 | 10.7 | 10.8 | 11.1 | 11.1 | 11.9 | 14.2 | 14.5 | 14.5 | 14.4 | 14.1 | |
FDA 510(k) Premarket Clearances — Revvity Group5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
FDA PMA Approvals & Supplements — Revvity Group | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 1 | 2 | |
FDA Medical Device Recalls Posted — Revvity Group | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
FDA MAUDE Adverse Event Reports — Revvity Group | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
U.S. Medical Device Industry Total — FDA 510(k) Clearances | 856 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
U.S. Medical Device Industry Total — FDA PMA Approvals & Supplements | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
Consolidated Revenue($M)5 | 729 | 730 | 711 | 772 | 699 | 720 | 665 | 729 | 684 | 692 | 650 | 696 | |
Operating Income (Continuing Operations)($M) | 95.1 | 89.3 | 75.9 | 112 | 81.9 | 90.8 | 72.2 | 119 | 98.2 | 85.7 | 44.1 | 77.2 | |
Research & Development Expense($M) | 48.1 | 49 | 57.9 | 58.2 | 50.8 | 53.3 | 53.6 | 49.2 | 49.1 | 48.1 | 50.4 | 49.6 | |
Selling, General & Administrative Expense($M) | 275 | 279 | 254 | 252 | 242 | 249 | 250 | 244 | 238 | 252 | 261 | 257 | |
Income from Continuing Operations($M) | 62.6 | 53.5 | 40.9 | 95.8 | 47.2 | 55.2 | 41.7 | 88.4 | 93.4 | 72.6 | 28.7 | 63.6 | |
Consolidated Net Income($M) | 62.3 | 51.8 | 40.7 | 98.4 | 46.7 | 53.9 | 42.2 | 94.6 | 94.4 | 55.4 | 26 | 78.6 | |
Cash & Cash Equivalents($M)8 | 593 | 1,023 | 860 | 920 | 931 | 992 | 1,138 | 1,165 | 1,230 | 1,248 | 998 | 913 | |
Accounts Receivable, Net($M) | 687 | 709 | 691 | 745 | 680 | 661 | 617 | 632 | 602 | 597 | 589 | 633 | |
Inventories, Net($M) | 389 | 379 | 388 | 380 | 380 | 389 | 381 | 368 | 405 | 401 | 414 | 428 | |
Property, Plant & Equipment, Net($M) | 451 | 456 | 466 | 479 | 497 | 499 | 487 | 482 | 518 | 503 | 504 | 510 | |
Goodwill($M) | 6,588 | 6,608 | 6,611 | 6,614 | 6,601 | 6,615 | 6,512 | 6,464 | 6,559 | 6,497 | 6,504 | 6,534 | |
Intangible Assets, Net($M) | 2,138 | 2,224 | 2,307 | 2,347 | 2,426 | 2,514 | 2,571 | 2,641 | 2,763 | 2,826 | 2,919 | 3,022 | |
Total Assets($M) | 11,490 | 12,046 | 11,997 | 12,168 | 12,139 | 12,363 | 12,361 | 12,393 | 12,770 | 13,425 | 13,433 | 13,565 | |
Long-Term Debt($M) | 2,634 | 2,633 | 2,632 | 2,631 | 2,631 | 3,214 | 3,168 | 3,151 | 3,186 | 3,163 | 3,165 | 3,178 | |
Total Stockholders' Equity($M) | 7,271 | 7,229 | 7,183 | 7,250 | 7,376 | 7,556 | 7,637 | 7,667 | 7,922 | 7,870 | 7,847 | 7,873 | |
Operating Cash Flow($M)4 | 167 | 192 | 115 | 182 | 139 | 134 | 128 | 174 | 148 | 159 | 148 | 197 | |
Capital Expenditures($M) | 14.3 | 11.1 | 19.8 | 20.2 | 18.5 | 18.9 | 16 | 24.5 | 22.3 | 22 | 17.8 | 24.1 | |
Common Stock Repurchases (Cash Outflow)($M) | 0.10 | 16 | 86.5 | 168 | 205 | 294 | 154 | 185 | 154 | 19.6 | 10.8 | 4.90 | |
Common Stock Dividends Paid($M) | 7.80 | 7.80 | 7.80 | 8 | 8.10 | 8.30 | 8.40 | 8.50 | 8.60 | 8.60 | 8.60 | 8.60 | |
Stock-Based Compensation Expense($M) | 9.80 | 10.7 | 8.70 | -4.10 | 9.10 | 10.1 | 7.70 | 5.10 | 10.5 | 10.5 | 11.7 | 7.20 | |
19 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Revvity, Inc. (formerly PerkinElmer, Inc. prior to May 2023) operates on a 52/53-week fiscal year ending on the Sunday nearest December 31; the latest completed company period is Q3 2026 (ended October 4, 2026).
- On July 31, 2026, Revvity signed a definitive agreement to divest its Immunodiagnostics business in China ('China IDX', ~6% of FY2025 revenue); beginning in 2026 earnings releases, management reports headline organic growth and forward guidance on a Pro Forma basis excluding China IDX.
- In Q1 2025, Revvity integrated Applied Genomics (previously in Diagnostics) into Life Sciences Solutions and reclassified prior periods back to FY2023; legacy pre-reclassification sub-lines are preserved as collapsed historical series through Q4 2024.
- Only cumulative-to-period derivations (Q4 = full year minus nine months from matching restatement vintages; quarterly cash flow = year-to-date minus prior year-to-date) are computed. Consolidated-minus-parent disaggregation is not applicable under consolidated US GAAP reporting.
- Independent external monthly indicators (openFDA device/IVD clearances, USAspending.gov federal prime contract obligations, and BLS Producer Price Indices for NAICS 334516/325413/621511) include October 2026 observations ahead of Q4 2026 corporate results.
Không hiện vì thiếu các kỳ gần đây (7)
- Top-level Life Sciences & Diagnostics Segment Revenue, Segment Profit, Regional Revenue (Americas, Europe, Asia), and Product vs. Service Revenue: omitted from custom sheet because XBRL segment series are already displayed natively in Core view
- Transaction Price Allocated to Remaining Performance Obligations (RPO): Revvity elects the ASC 606 practical expedient for contracts <=1 year and states that unsatisfied RPO >1 year is immaterial (not numerically disclosed)
- Oxford Immunotec Limited (UK Companies House #04516079) Audited Statutory Series (FY2020–FY2024): latest filed UK statutory accounts cover through December 29, 2024; FY2025 accounts are not yet due at Companies House (missing FY2025 for two-year continuity)
- Signals Software ARR (>$100M in 2026E), APV (>$130M in 2020; >$275M in 2026E), Active Users (1M+), Customers (4,000+), Cumulative Babies Screened (>868M), and Compliance Training Completion (>98% / >99%): excluded because disclosed only as inequality bounds rather than exact point figures
- Initial FY2025 Scope 3 Greenhouse Gas Emissions Breakdown (103,453 tCO2e across 6 categories in 2026 Impact Report): first disclosed for baseline year 2025 only (single annual observation, lacks two consecutive years)
- Global Babies Screened Annually (~40M/year): stated qualitatively as a multi-year rounded benchmark in narrative Impact Report highlights rather than an audited annual time-series table through FY2025
- U.S. Producer Price Index — Analytical Laboratory Instrument Manufacturing (NAICS 334516) › U.S. Medical & Diagnostic Laboratories Industry Revenue (Census QSS): lacks continuous multi-period coverage through latest reporting period
Dữ liệu cập nhật 2026-11-18.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Revvity Signals Software & Contract Backlog Indicators (Key #1)
Specialty Diagnostics Franchises & Organic Growth Drivers (Key #2)
Life Sciences Solutions Franchise & Manufacturing Inventory Pipeline (Key #3)
Organic Growth Bridge, Pro Forma Portfolio & Full-Year Guidance (Key #4)
Segment Cost Structure & Operating Margins (ASU 2023-07)
Share Repurchase Authorization, Intangibles Schedule, PP&E & Reserves
Global Workforce, Workplace Safety & Environmental Operations (Impact Reports)
Horizon Discovery Biosciences & Revvity Discovery (UK Subsidiary Statutory Accounts)
External Regulatory, Federal Contracting & Industry Benchmarks
Consolidated Financial Context (GAAP)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Revvity
- SEC Form 10-Q (FY2026Q3), filed 2026-11-10 ↗
- SEC Form 10-K (FY2025), filed 2026-02-24 ↗
- Revvity 2026 Impact Report (FY2022–FY2025 ESG Data Reconciliation) ↗
- U.S. FDA Center for Devices and Radiological Health — openFDA 510(k) Premarket Notification Database (Revvity / PerkinElmer / EUROIMMUN / Oxford Immunotec) ↗
- SEC Form 10-K, filed 2026-02-24 ↗
- SEC Form 10-K (FY2024), filed 2025-02-25 ↗
- SEC Form 8-K (q32026pressrelease.htm), filed 2026-11-03 ↗
- SEC Form 8-K (q42025pressrelease.htm), filed 2026-02-02 ↗
- Revvity Q3 2026 Earnings Call Transcript (Nov 3, 2026) ↗
- Revvity Q4 2025 Earnings Call Transcript (Feb 2, 2026) ↗
- UK Companies House #05978215 — Horizon Discovery Biosciences Limited (uk_05978215_AA_2025.pdf) ↗
- UK Companies House #08921143 — Revvity Discovery Limited (Horizon Discovery) (uk_08921143_AA_2025.pdf) ↗
See a number that looks wrong?